Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 9:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 28 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: AMR Clear all
Completed Phase 1Phase 2 Interventional Results available

Phase 1-2 Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma

NCT01355705
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Amrubicin, Lenalidomide, Dexamethasone, Aspirin, Pegfilgrastim
Drug
Lead sponsor
Michaela Liedtke
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 17, 2018 · Synced Jul 22, 2026, 9:03 AM EDT
Enrolling by invitation Phase 3 Interventional

A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR) or Microvascular Inflammation (MVI) (TRANSCEND/TRANSPIRE LTE)

NCT07444489
View directory record Official record
Conditions
Antibody-mediated Rejection, Microvascular Inflammation
Interventions
Felzartamab
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 75 Years
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
2
States / cities
Los Angeles, California • West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Jul 22, 2026, 9:03 AM EDT
Withdrawn Phase 2 Interventional

Study of Amrubicin With or Without Herceptin in Patients With Metastatic Breast Cancer

NCT00380835
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Amrubicin
Drug
Lead sponsor
Celgene Corporation
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2007
U.S. locations
28
States / cities
New Milford, Connecticut • Sharon, Connecticut • Torrington, Connecticut + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2008 · Synced Jul 22, 2026, 9:03 AM EDT
Completed Phase 1 Interventional

A Phase I Study to Assess the Safety, Pharmacokinetics, and Potential Effects of Amrubicin on the QT/QTc Interval in Cancer Patients With Advanced Solid Tumors.

NCT00915083
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
Amrubicin
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
8
States / cities
La Jolla, California • Santa Monica, California • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2019 · Synced Jul 22, 2026, 9:03 AM EDT
Completed Phase 2 Interventional Results available

Amrubicin Chemotherapy as First Line in Metastatic or Unresectable Soft Tissue Sarcoma

NCT01259375
View directory record Official record
Conditions
Soft Tissue Sarcoma
Interventions
Amrubicin
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
Santa Monica, California • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 16, 2017 · Synced Jul 22, 2026, 9:03 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Eculizumab to Prevent Antibody-mediated Rejection in ABO Blood Group Incompatible Living Donor Kidney Transplantation

NCT01095887
View directory record Official record
Conditions
Kidney Transplant
Interventions
Eculizumab
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 19, 2015 · Synced Jul 22, 2026, 9:03 AM EDT
Not yet recruiting No phase listed Observational

Retrospective Kinetic Safety Evaluation of an Intravenous Micellar Excipient Platform

NCT07609069
View directory record Official record
Conditions
Drug Related Side Effects and Adverse Reactions, Infusion Reactions
Interventions
PIV-850 (850-picometer Dual-NCE Acidic Matrix), Legacy Heterogeneous Payload (Micellar Vehicle)
Drug
Lead sponsor
PICO IV, Inc.
Industry
Eligibility
18 Years and older
Enrollment
625 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jul 22, 2026, 9:03 AM EDT
Completed Phase 2 Interventional

Study Comparing Amrubicin Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Responded to Prior Therapy.

NCT00319969
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Amrubicin, Topotecan
Drug
Lead sponsor
Celgene Corporation
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
47
States / cities
Birmingham, Alabama • Phoenix, Arizona • Berkeley, California + 40 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2009 · Synced Jul 22, 2026, 9:03 AM EDT
Not listed No phase listed Observational

NCAMR-CAMR Allosure Study

NCT04217343
View directory record Official record
Conditions
Transplant Failure
Interventions
Allosure/Allomap/Cytokines testing
Diagnostic Test
Lead sponsor
Tampa General Hospital
Other
Eligibility
18 Years to 99 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 21, 2022 · Synced Jul 22, 2026, 9:03 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR)

NCT06503731
View directory record Official record
Conditions
Antibody-mediated Rejection
Interventions
Efgartigimod PH20 SC - prefilled syringe, Placebo PH20 SC - prefilled syringe
Combination Product · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years to 80 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
8
States / cities
Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Jul 22, 2026, 9:03 AM EDT
Recruiting Phase 1 Interventional

A Phase 1 Clinical Trial of Siltuximab for the Treatment of Antibody-Mediated Rejection After Lung Transplantation

NCT06990711
View directory record Official record
Conditions
Antibody Mediated Rejection of Lung Transplant
Interventions
Siltuximab, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
St Louis, Missouri • Saint Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Jul 22, 2026, 9:03 AM EDT
Recruiting Phase 2 Interventional

Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation

NCT06744647
View directory record Official record
Conditions
Antibody-Mediated Rejection, Kidney Transplantation, Biopsy-proven Histologic Scores, AMR
Interventions
ALXN2030, Placebo
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
23
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Jul 22, 2026, 9:03 AM EDT
Terminated Phase 3 Interventional Results available

Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients

NCT03744910
View directory record Official record
Conditions
Antibody-mediated Rejection
Interventions
Clazakizumab, Physiologic saline solution
Biological · Drug
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years to 75 Years
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
49
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2025 · Synced Jul 22, 2026, 9:03 AM EDT
Completed Phase 2 Interventional Results available

A Trial of Amrubicin and Carboplatin With Pegfilgrastim in Patients With Extensive-Stage Small Cell Lung Cancer

NCT01076504
View directory record Official record
Conditions
Extensive-Stage Small Cell Lung Cancer
Interventions
Amrubicin, Carboplatin, Pegfilgrastim
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
20
States / cities
Jonesboro, Arkansas • Fort Myers, Florida • Lakeland, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated May 4, 2016 · Synced Jul 22, 2026, 9:03 AM EDT
Terminated Early Phase 1 Interventional

Pilot Study of Treatment for Subclinical AMR (Antibody-mediated Rejection) in Kidney Transplant Recipients

NCT03380936
View directory record Official record
Conditions
Kidney Transplant Rejection
Interventions
Tacrolimus Extended Release Oral Tablet [Envarsus], Plasma Exchange and IVIG (Intravenous Immunoglobulin )
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 79 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 26, 2020 · Synced Jul 22, 2026, 9:03 AM EDT
Active, not recruiting Phase 2 Interventional

BIVV020 (SAR445088) in Prevention and Treatment of Antibody-mediated Rejection (AMR)

NCT05156710
View directory record Official record
Conditions
Transplant Rejection
Interventions
BIVV020 (SAR445088), Intravenous immunoglobulin (IVIg), Rituximab or biosimilar, Antithymocyte globulin (ATG), Tacrolimus, Mycophenolate, Corticosteroids
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Jul 22, 2026, 9:03 AM EDT
Recruiting Phase 4 Interventional

Optimization of Beta-lactam Dosing in Critically Ill Patients With Cystatin C (OPTIMIZE-GNI)

NCT06709521
View directory record Official record
Conditions
Bacterial Infection
Interventions
Iohexol
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
10
States / cities
Torrance, California • Detroit, Michigan • Royal Oak, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Jul 22, 2026, 9:03 AM EDT
Completed Phase 2 Interventional

Study of Amrubicin in Patients With Small Cell Lung Cancer Refractory or Progressive to Prior Therapy

NCT00375193
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Amrubicin
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
44
States / cities
Phoenix, Arizona • Lone Tree, Colorado • Ocala, Florida + 38 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2019 · Synced Jul 22, 2026, 9:03 AM EDT
Completed Phase 1 Interventional

Amrubicin + Cyclophosphamide in Advanced Solid Organ Malignancies

NCT00890955
View directory record Official record
Conditions
Lung Cancer
Interventions
Amrubicin, Cyclophosphamide
Drug
Lead sponsor
Lawrence Einhorn
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
10
States / cities
Springdale, Arkansas • Newark, Delaware • Galesburg, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2015 · Synced Jul 22, 2026, 9:03 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Dosing Regimen of Eculizumab Added to Conventional Treatment in Positive Cross Match Living Donor Kidney Transplant

NCT00670774
View directory record Official record
Conditions
Kidney Transplant
Interventions
Eculizumab
Drug
Lead sponsor
Mark Stegall
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 25, 2018 · Synced Jul 22, 2026, 9:03 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) in Adult Renal Transplant Recipients

NCT03221842
View directory record Official record
Conditions
Antibody-mediated Rejection
Interventions
C1-esterase inhibitor, Placebo
Drug
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
13
States / cities
Birmingham, Alabama • Phoenix, Arizona • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced Jul 22, 2026, 9:03 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)

NCT06685757
View directory record Official record
Conditions
Antibody-mediated Rejection
Interventions
Felzartamab, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 75 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
26
States / cities
Los Angeles, California • Orange, California • San Bernardino, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jul 22, 2026, 9:03 AM EDT
Terminated Phase 3 Interventional Results available

A Multicenter Study to Evaluate the Efficacy and Safety of Cinryze® for the Treatment of Acute Antibody-mediated Rejection in Participants With Kidney Transplant

NCT02547220
View directory record Official record
Conditions
Acute Antibody-Mediated Rejection (AMR)
Interventions
Cinryze®, Placebo
Biological · Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 70 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
29
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2020 · Synced Jul 22, 2026, 9:03 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic Malignancies

NCT01364727
View directory record Official record
Conditions
Thymoma, Thymus Cancer, Thymic Carcinoma
Interventions
Amrubicin
Drug
Lead sponsor
Heather Wakelee
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
2
States / cities
Stanford, California • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 15, 2019 · Synced Jul 22, 2026, 9:03 AM EDT